Aus coViki
Wechseln zu: Navigation, Suche
PHA Biologicals

32278362 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
32382744 2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.
32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32436460 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
32554621 2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.

32553760 2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.

32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32485316 2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
32540603 2020. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.

Meine Werkzeuge